Patents by Inventor Inger Sandlie

Inger Sandlie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11319383
    Abstract: The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: May 3, 2022
    Assignee: Universitetet | Oslo
    Inventors: Jan Terje Andersen, Stian Foss, Inger Sandlie
  • Patent number: 11306318
    Abstract: The present invention provides a vector construct comprising the following components: (i) a sequence encoding a signal peptide which directs proteins into the Tat secretory pathway; and (ii) a sequence encoding a fluorophore fused to a sequence encoding a pVIII phage coat protein. Nucleic acid molecules comprising components (i) and (ii) are also provided, together with phage particles comprising such vectors or nucleic acid molecules and expressing a fluorophore-pVIII fusion protein on the surface. Methods for producing such fluorescent phage particles are also provided.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: April 19, 2022
    Assignee: NEXTERA AS
    Inventors: Geir Åge Løset, Terje Frigstad, Sebastian Berge-Seidl, Nicolay Rustad Nilssen, Inger Sandlie
  • Publication number: 20210147552
    Abstract: The present invention relates generally to the field of antigen binding proteins such as antibodies, in particular those which bind to HLA-DQ2.5:DQ2.5-glia-?1a, or which bind to HLA-DQ2.5:DQ2.5-glia-?2. The invention further relates to compositions and immunoconjugates comprising such antibodies and to methods of producing such antibodies. The invention also relates to methods and uses which employ such antibodies, for example in the treatment of celiac disease.
    Type: Application
    Filed: February 13, 2019
    Publication date: May 20, 2021
    Inventors: Geir Åge LØSET, Lene Støkken HØYDAHL, Inger SANDLIE, Ludvig Magne SOLLID, Rahel FRICK
  • Publication number: 20200385442
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: May 22, 2020
    Publication date: December 10, 2020
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Patent number: 10781245
    Abstract: The present invention relates to albumin variants with an improved affinity for the neonatal Fc receptor (FcRn) and uses thereof, and in particular to the use of such albumin variants as carriers for immunogens. In some embodiments, the present invention relates to vaccines (e.g., vaccines for mucosal delivery) comprising albumin/immunogen fusion proteins.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: September 22, 2020
    Assignee: University of Oslo
    Inventors: Jan Terje Andersen, Inger Sandlie, Malin Bern
  • Publication number: 20200255843
    Abstract: The present invention provides a vector construct comprising the following components: (i) a sequence encoding a signal peptide which directs proteins into the Tat secretory pathway; and (ii) a sequence encoding a fluorophore fused to a sequence encoding a pVIII phage coat protein. Nucleic acid molecules comprising components (i) and (ii) are also provided, together with phage particles comprising such vectors or nucleic acid molecules and expressing a fluorophore-pVIII fusion protein on the surface. Methods for producing such fluorescent phage particles are also provided.
    Type: Application
    Filed: November 5, 2018
    Publication date: August 13, 2020
    Applicant: Nextera AS
    Inventors: Geir Åge LØSET, Terje FRIGSTAD, Sebastian BERGE-SEIDL, Nicolay Rustad NILSSEN, Inger SANDLIE
  • Patent number: 10696732
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 30, 2020
    Assignee: ALBUMEDIX, LTD
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Patent number: 10640761
    Abstract: The present invention relates to vectors, methods and systems for polypeptide display and selection. Specifically, the present invention relates to vectors, methods, and systems for multivalent phage display using pIX protein of filamentous phage and helper phage.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: May 5, 2020
    Assignee: University of Oslo
    Inventors: Geir Age Loset, Inger Sandlie
  • Publication number: 20200102368
    Abstract: The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: October 22, 2019
    Publication date: April 2, 2020
    Inventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Ann Delahay
  • Publication number: 20190201496
    Abstract: Provided herein, in some aspects, are compositions and methods to inhibit AFP interactions with ?2M and/or Class I-related molecule interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate AFP interactions with ?2M and/or Class I-related molecule in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels is desired to increase immunosuppression or enhance organ regeneration.
    Type: Application
    Filed: September 14, 2017
    Publication date: July 4, 2019
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., UNIVERSITY OF OSLO
    Inventors: Richard S. BLUMBERG, Michal PYZIK, Amit GANDHI, Inger SANDLIE, Kine Marita Knudsen SAND, Jan Terje ANDERSEN
  • Publication number: 20190135895
    Abstract: The present invention relates to albumin variants with an improved affinity for the neonatal Fc receptor (FcRn) and uses thereof, and in particular to the use of such albumin variants as carriers for immunogens. In some embodiments, the present invention relates to vaccines (e.g., vaccines for mucosal delivery) comprising albumin/immunogen fusion proteins.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 9, 2019
    Inventors: Jan Terje Andersen, Inger Sandlie, Malin Bern
  • Publication number: 20190113519
    Abstract: The present invention relates to a method of assessing pharmacokinetic properties of a variant of human serum albumin using a non-primate animal species where the native albumin of the animal provides minimal competition for HSA binding to the FcRn receptor in said animal. In the non-primate animal species, the binding affinity of wild type HSA to the native FcRn of said animal is the same as or higher than the binding affinity of the native albumin of said animal to the native FcRn. The present invention also relate to animal models which are particularly suitable for assessing pharmacokinetics of human serum albumin variants.
    Type: Application
    Filed: May 7, 2018
    Publication date: April 18, 2019
    Inventors: Jason Cameron, Darrell Sleep, Jan Terje Andersen, Inger Sandlie
  • Patent number: 10233228
    Abstract: The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: March 19, 2019
    Assignee: ALBUMEDIX LTD
    Inventors: Andrew Plumridge, Darrell Sleep, Inger Sandlie, Jan Terje Andersen, Jason Cameron, Leslie Evans, Steven Athwal, Elizabeth Allan, Esben Peter Friis
  • Publication number: 20190077883
    Abstract: The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.
    Type: Application
    Filed: March 14, 2017
    Publication date: March 14, 2019
    Applicant: UNIVERSITETET I OSLO
    Inventors: Jan Terje ANDERSEN, Stian FOSS, Inger SANDLIE
  • Patent number: 10208102
    Abstract: The present invention relates to albumin variants with an improved affinity for the neonatal Fc receptor (FcRn) and uses thereof, and in particular to the use of such albumin variants as carriers for immunogens. In some embodiments, the present invention relates to vaccines (e.g., vaccines for mucosal delivery) comprising albumin/immunogen fusion proteins.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: February 19, 2019
    Assignee: UNIVERSITY OF OSLO
    Inventors: Jan Terje Andersen, Inger Sandlie, Malin Bern
  • Publication number: 20180265570
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: May 14, 2018
    Publication date: September 20, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180222963
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: January 12, 2018
    Publication date: August 9, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180162925
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: January 12, 2018
    Publication date: June 14, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180105576
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 19, 2017
    Publication date: April 19, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180105577
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 19, 2017
    Publication date: April 19, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis